Clinical Trials
Julie S. Burt
Supervisor, Ophthalmology Clinical Trials and Regulatory Affairs
New England Eye Center
Tufts Medical Center
800 Washington Street, #450
Boston, MA 02111
617-636-0747 Fax: 617-636-4866
Email:
jburt@tuftsmedicalcenter.org
Therapeutic Area
Retina/OphthalmologyPrincipal Investigator
Elias Reichel, MDTitle
Phase II, Multicenter, Double-Masked, Placebo Controlled, Parallel Group Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of GSK933776 in Adult Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)Brief Summary
To test the safety of GSK933776 and to look at any changes in geographic atrophy of the eye over time.
Inclusion Criteria
- Evidence of AMD confirmed by the presence of at least 1 druse >125 um diameter in either eye
Exclusion Criteria
- Additional eye disease in the study eye that could compromise assessment of BCVA, confound BCVA assessment, or imaging of the posterior pole
Study Requirements
18 study visits over a two year period, additional MRI visits, blood draws, IV infusion
Age Range
55 and overGender
BothPayment
A stipend will be provided for each completed study visit. Transportation to and from your study visits will also be provided to you in addition to the study visit stipend.Contact
Olivia Sahnas617-636-1051
Therapeutic Area
Glaucoma/OphthalmologyPrincipal Investigator
Cynthia Mattox, MDTitle
A Prospective, Randomized, Comparative, Multicenter Clinical Study To Assess The Safety And Effectiveness Of The Transcend Cypass Glaucoma Implant In Patients With Open Angle Glaucoma Undergoing Cataract SurgeryBrief Summary
The purpose of this research study is to evaluate the safety and effectiveness of the CyPass Implant in lowering intraocular pressure (IOP) in glaucomatous eyes in conjunction with cataract surgery, as compared to eyes treated with cataract surgery alone.Inclusion Criteria
- A diagnosis of primary open angle glaucoma (POAG).
Study Requirements
13 visitsAge Range
45 and overGender
BothPayment
$50 per completed visitContact
Melody Velasquez617-636-5489
Therapeutic Area
Retina/OphthalmologyPrincipal Investigator
Elias Reichel, MDTitle
Age Related Macular DegenerationBiomarkers for Dry Age-Related Macular Degeneration
Brief Summary
This study involves two new tests that could detect whether people have a common eye disease called dry age-related macular degeneration, or dry AMD. These tests may also be useful for monitoring people who already have dry AMD, and deciding whether medication is helping them.
Sponsor: Novartis
Inclusion Criteria
Diagnosed with age-related macular degeneration
Age Range
55 years and olderGender
BothContact
Olivia Sahnas
Clinical Research Coordinator, at
617-636-1051
